Vallon Pharmaceuticals

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on A pril 29 th at 10:30 AM ET

Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines in the treatment of ADHD, a ~$9 billion U.S. market1

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval

Altimeter Growth

Dragon Victory

Mackinac Financial

Nicolet Bankshares

Optibase

B. Riley Financial

Riot Blockchain

Tian Ruixiang Holdings

Xunlei

Pre-market movers on Tuesday include ZOM stock, RIOT stock and AGC stock, following all sorts of big stock market news. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning appeared first on InvestorPlace.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning

- Pivotal data from lead program, ADAIR, expected in second half 2021

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 and 10, 2021.

Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

- Accomplished executive leader with more than 30 years of experience in finance and operations

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors

Adagene

Baosheng Media Group Holdings

Bumble

Bioventus

Decibel Therapeautics

Viant Technology

Longeveron

NexImmune

Cloopen Group Holding

Global Internet of People

Signify Health

Urban-gro

The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble, which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group, which bagged the biggest pop of 2021 to date.

U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO Week

PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the closing of its initial public offering of 2,250,000 shares of common stock at a public price offering of $8.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Vallon, were $18.0 million. In addition, Vallon has granted the underwriters a 45-day option to purchase up to an additional 337,500 shares of Vallon's common stock at the initial public offering price, less underwriting discounts and commissions.

Vallon Pharmaceuticals Announces Closing of Initial Public Offering

PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a public offering price of $8.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 337,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering

News for Vallon Pharmaceuticals Stock (VLON)